Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
Independent data safety monitoring board (DSMB) formally recommends investigational combination therapy advance to Phase 3…